Patient Rating:

No Rating Available?

Elizabeth Ann Raetz, M.D.

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address

Bio

Dr. Raetz received her medical degree and completed residency training at the University of Wisconsin. She completed a fellowship in Pediatric Hematology-Oncology at the University of Utah and was a member of the faculty from 1998 to 2002. Dr. Raetz returned to the faculty of the University of Utah in 2014, where she is a Professor in the Division of Pediatric Hematology-Oncology. She is board-certified in Pediatric Hematology-Oncology.

Dr. Raetz’s clinical interests include the treatment of all pediatric cancers and hematologic disorders, with an emphasis on acute lymphoblastic leukemia (ALL) and lymphoma. She serves as the Medical Director of the High Risk Leukemia and Lymphoma Program. She is also actively involved in developing therapy for adolescents and young adults (AYAs) with ALL.

Dr. Raetz’s research focuses on clinical and translational studies in ALL and she is an active member of the Children’s Oncology Group and Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Dr. Raetz serves on several committees within the Huntsman Cancer Institute and is the chair of the Data and Safety Monitoring Committee.

Board Certification and Academic Information

Academic Departments Pediatrics - Professor (Clinical)
Academic Divisions Pediatric Hematology/Oncology
Board Certification American Board of Pediatrics (Sub: Ped Hematology-Oncology)
Cancer Center Programs Experimental Therapeutics

Academic Profile

Research Interests

  • Acute Lymphoblastic Leukemia

Board Certification and Academic Information

Academic Departments Pediatrics - Professor (Clinical)
Academic Divisions Pediatric Hematology/Oncology
Board Certification American Board of Pediatrics (Sub: Ped Hematology-Oncology)
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 588-2680 Primary Children's Hospital
Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City, UT 84113

Academic Bio

Dr. Raetz is a Professor in the Division of Pediatric Hematology-Oncology. She presently serves as the Medical Director of the High Risk Leukemia and Lymphoma Program at Primary Children’s Hospital and as the chair of the Data and Safety Monitoring Committee at the Huntsman Cancer Institute. She is a member of the Experimental Therapeutics Program.

Her research focuses on clinical and translational studies in childhood acute lymphoblastic leukemia (ALL) with a special interest in developing clinical trials for pediatric patients with high risk and relapsed leukemia and investigating predictors for common toxicities associated with ALL treatment. She has developed studies to determine risk factors for the development of steroid-related bone toxicity. Her research is currently supported by the National Cancer Institute and the Leukemia and Lymphoma Society.

Dr. Raetz completed her undergraduate studies at Duke University and the University of Wisconsin-Madison, her medical education at the University of Wisconsin-Madison, where she was elected into Alpha Omega Alpha Honor Medical Society, and her fellowship training at the University of Utah. She returned to the faculty of the University of Utah in 2014. Dr. Raetz has been an active member of the National Children’s Oncology Group (COG) ALL Committee for the past 10 years, serving on the Executive Committee and as the study chair for clinical trials in relapsed ALL and disease classification. She presently serves as a Vice Chair for the COG ALL Disease Committee, overseeing frontline clinical trials and ALL Disease Committee liaison for the COG Adolescent and Young Adult Committee.

Education

Education History

Type School Degree
Fellowship University of Utah School of Medicine
Pediatric Hematology/Oncology
Fellow
Residency University of Wisconsin
Pediatrics
Resident
Internship University of Wisconsin
Pediatrics
Intern
Professional Medical University of Wisconsin
Medicine
M.D.
Undergraduate University of Wisconsin
History of Science
B.S.
Undergraduate Duke University

Publications

Selected Provider Publications

Journal Article

  1. Hunger SP, Loh ML, Whitlock JA, Winick NJ, Carroll WL, Devidas M, Raetz EA (2013). Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer, 60(6), 957-63.
  2. Heerema NA, Carroll AJ, Devidas M, Loh ML, Borowitz MJ, Gastier-Foster JM, Larsen EC, Mattano LA Jr, Maloney KW, Willman CL, Wood BL, Winick NJ, Carroll WL, Hunger SP, Raetz EA (2013). Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. J Clin Oncol, 31(27), 3397-402.
  3. Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A, Carroll WL (2013). A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL): A Report From the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. J Pediatr Hematol Oncol.
  4. Carroll WL, Raetz EA (2012). Clinical and laboratory biology of childhood acute lymphoblastic leukemia. J Pediatr, 160(1), 10-8.
  5. Raetz EA, Bhatla T (2012). Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematology Am Soc Hematol Educ Program, 2012, 129-36.
  6. Hogan LE, Raetz EA (2010). Dying to predict outcome. Pediatr Blood Cancer, 55(1), 5-6.
  7. Carroll WL, Raetz EA (2008). "When can I go home?"-seeking ways to lower the burden on patients and families. Pediatr Blood Cancer, 51(3), 318-9.
  8. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC (2008). Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol, 26(22), 3756-62.
  9. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL (2008). Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol, 26(24), 3971-8.

Review

  1. McNeer JL, Raetz EA (2012). Acute lymphoblastic leukemia in young adults: which treatment? [Review]. Curr Opin Oncol, 24(5), 487-94.
  2. Raetz EA, Salzer WL (2010). Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. [Review]. J Pediatr Hematol Oncol, 32(7), 554-63.
  3. Carroll W, Hunger SP, Borowitz M, Bhojwani D, Willman C, Devidas M, Schultz K, Loh M, Raetz E (2008). Risk-Adapted Therapy for Children with Acute Lymphoblastic Leukemia (ALL): the Children's Oncology Group (COG) Approach. [Review]. Annals of Hematology, 87(Suppl 1), S42-44.

Clinical Trials

Video & News